The Leeds Centre for Personalised Medicine and Health in the UK has launched a clinical trial to investigate the use of a blood protein test in detecting the risk of disease.

Developed by US-based biotech SomaLogic, the test is based on proteomics and is said to indicate an individual’s real-time health status.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The test is designed to measure changes in the levels of 5,000 proteins in blood in order to calculate the risk of a person developing certain disorders, including diabetes and heart disease.

“The researchers will use personalised health insights derived from the blood test to advise people on lifestyle changes in order to help prevent the onset of type 2 diabetes.”

It is based on SomaLogic platform, which delivers insights that allow biomarker discovery, diagnostics development, pharmaceutical discovery and development, and health management.

During the current trial, Leeds researchers will use personalised health insights derived from the blood test to advise people on lifestyle changes in order to help prevent the onset of type 2 diabetes.

The cost of diabetes to the NHS in the UK is said to be over £1.5m an hour which is around 10% of the NHS budget for England and Wales.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In addition, the trial will assess the test’s effectiveness. The trial will be expanded to other clinical sites based on the findings at the Leeds Centre.

Leeds Centre for Personalised Medicine and Health head Dr Michael Messenger said: “Personalised medicine lets us take a deeper look at each person’s individual biology so we can better understand what the right advice or treatment, at the right time, might be for that person.

“Advances in science, medicine and new technologies, such as this test, help us do exactly that, which is great news for patients and their families. The test results will mean GPs can discuss with those patients lifestyle changes they could make to help them avoid the onset of diabetes, for example, helping them live healthier lives for longer.”

At present, Leeds Centre for Personalised Medicine and Health has formed multiple alliances, including with NHS Leeds Clinical Commissioning Group and local GPs, to enrol 1,000 patients from up to 24 general practices.

Additional reporting by Charlotte Edwards. 

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact